Sign in to view content

Effects of the Mitochondria-Targeted Drug Elamipretide on Leakage-Independent Vision Loss in Fellow Eyes with Neovascular AMD in the ReCLAIM Study

Priyatham (Prithu) S Mettu, MD

Video
Published 2019

Related

Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen
Michael J Allingham, MD, PhD
Annual Meeting Talks
2019
Suspected Multiple Evanescent White Dot Syndrome
Stuart Alfred, CRA, OCT-C
Retina Image Bank: Images of the Week
2015
2019 Winning Pitch Challenge Winner
Updates from the Field

Category: AMD-Non-neovascular

See more